Stock analysis, AI verdict, fundamentals & technical signals
Rating: NEUTRAL
Price: $1.56 Analyst target: $10.83 Upside: 594.23%
Nkarta, Inc., a clinical-stage biopharmaceutical company, develops and markets cell therapies for the treatment of cancer. The company is headquartered in South San Francisco, California.
See the full interactive analysis & chart →Informational only — not investment advice.